BillionToOne Inc (BLLN) Stock Analysis
Verdict: HOLD
High growth in molecular diagnostics is priced in at 137x P/E, but sequential margin decay and aggressive C-suite liquidation signal severe downside.
Investment score: 42/100
Analysis as of
Is BillionToOne Inc stock worth reviewing? AI model thesis
The model score of 42/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 80/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
BillionToOne Inc opportunities and risks
What speaks for BLLN
- Commercial expansion in liquid biopsy and multi-gene panels
What speaks against BLLN
- Aggressive executive equity liquidation signals operational ceiling
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BLLN | 137.2x | 11.0x | 78.6x | 71.3% | 8.4% | 0.8% |
| RDNT | n/a | 2.3x | 20.1x | 9.7% | -0.9% | -1.1% |
| OPCH | 23.3x | 0.8x | 13.8x | 18.2% | 3.7% | 7.5% |
| LFST | 92.1x | 2.9x | 35.1x | 33.6% | 3.2% | 4.5% |
| CRVL | 33.8x | 3.9x | 19.8x | 23.9% | 11.7% | 2.9% |
| AVAH | 9.2x | 1.0x | 13.6x | 32.0% | 10.6% | 6.2% |
| Peer median | 23.3x | 2.3x | 19.8x | 23.9% | 3.7% | 4.5% |
Frequently asked questions about BillionToOne Inc (BLLN)
Is BLLN stock a good investment?
The cached TradeMates AI model rates BillionToOne Inc as HOLD with an investment score of 42/100. The model score of 42/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is BLLN stock a buy?
The TradeMates model verdict for BLLN is HOLD with an investment score of 42/100. Treat this as a model signal to review, not a personal buy recommendation.